Antagonist G
CAS: 115150-59-9
Ref. 3D-FA73202
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 100µg | Discontinued | ||
| 250µg | Discontinued | ||
| 500µg | Discontinued |
Product Information
- Arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide
- Arg-trp-N-methyl-phe-trp-leu-met-NH2
- H-Arg-D-trp-N(Me)phe-D-trp-leu-met-NH2
- L-Arginyl-O-tryptophyl-N-methyl-L-phenylalanyl-D-tryptophyl-L-leucyl-L-methioninamide
- RW-N(Me)F-Wlm-NH2
- L-Methioninamide, L-arginyl-O-tryptophyl-N-methyl-L-phenylalanyl-D-tryptophyl-L-leucyl-
- N~5~-(diaminomethylidene)-L-ornithyl-D-tryptophyl-N-methyl-L-phenylalanyl-D-tryptophyl-L-leucyl-L-methioninamide
- N~5~-(diaminomethylidene)ornithyltryptophyl-N-methylphenylalanyltryptophylleucylmethioninamide
- (Arg6,D-Trp7,9,N-Me-Phe8)-Substance P (6-11)
Antagonist G is a trifluoroacetic acid derivative that binds to the CB2 receptor. It has been shown to inhibit cancer cell growth and reduce the size of breast tumors in mice. Antagonist G also inhibits the production of inflammatory cytokines by macrophages and reduces immune responses, which may be due to its ability to block toll-like receptor 4 (TLR4) signaling. Antagonist G has also shown anti-inflammatory properties in animal models of autoimmune disease, including experimental autoimmune encephalomyelitis (EAE). This drug also has antibacterial and antifungal properties as well as an ability to stimulate probiotic bacteria. Antagonist G can be used for the treatment of radiation-induced side effects such as leukemic stem cells, glutamate dehydrogenase, or infectious diseases such as tuberculosis or malaria.
